VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2023 | The current state of MRD testing in colorectal cancer

Afsaneh Barzi, MD, PhD, City of Hope, Duarte, CA, provides an overview of the clinical impact of minimal residual disease (MRD) testing in colorectal cancer, and strategies to optimize sensitivity. False negatives may occur during testing, and there is no definite treatment regimen for patients who are MRD positive post-surgery. MRD testing alone should additionally not determine whether patients should receive adjuvant therapy. Dr Barzi also highlights disparities in the use of MRD testing. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter